Cancer Studies

Professor Karen Brown

• Preclinical and early clinical development of novel cancer chemopreventive agents
• Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy

Professor Don J. L. Jones

• Translation of candidate biomarkers to clinical use.
• Use of high resolution LC-MS in the discovery and verification of biomarkers.
• Investigation of protein quantification using Ion mobility.
• Translation of candidate biomarkers to clinical use.
• Use of high resolution LC-MS in the discovery and verification of biomarkers.
• Investigation of protein quantification using Ion mobility.

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
• Investigating and exploiting metabolic vulnerabilities in carcinogenesis
• Using circulating cell-free DNA for early detection of cancer

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies
• Improving information exchange in oncology consultations

Dr Cristina Tufarelli 

• Determine which repetitive elements are active in precancerous and cancerous cells
• Understanding what causes activation of repetitive elements
• Establish activation of which repetitive elements plays functional roles in cancer
• Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies
• Antibody therapy of lymphoid malignancies
• Development and assessment of novel agents for therapy of B-cell malignancies

Dr David Guttery

• Analysis of circulating cancer biomarkers through liquid biopsy
• Molecular approaches to aid early detection of cancer
• Molecular mechanisms of resistance to targeted therapy
• Utility of artificial intelligence for early detection and improving therapy stratification

Dr Esther Moss

• Analysis of circulating endometrial cancer biomarkers through liquid biopsy
• Robotic surgery for management of endometrial cancer
• Patient-initiated follow up for low-risk endometrial cancer
• Use of ex-vivo models for personalising therapies

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
• Investigating and exploiting metabolic vulnerabilities in carcinogenesis
• Using circulating cell-free DNA for early detection of cancer

Professor Jacqui Shaw

• Analysis of circulating cancer biomarkers through liquid biopsy
• Molecular approaches to aid early detection of cancer
• Molecular mechanisms of resistance to targeted therapy

Dr Matt Ahearne

• Developing new diagnostic and therapeutic approaches in T-cell lymphoma
• Targeting the microenvironment in B-cell lymphoma

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies
• Antibody therapy of lymphoid malignancies
• Development and assessment of novel agents for therapy of B-cell malignancies

Dr Harriet Walter

• Delivery of Phase I portfolio across haematological malignancies and solid tumours
• Therapeutic drug development
• Development and assessment of novel agents in the treatment of B-cell malignancies

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies
• Antibody therapy of lymphoid malignancies
• Development and assessment of novel agents for therapy of B-cell malignancies

Professor Dean Fennell

• Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Dr David Guttery

• Analysis of circulating cancer biomarkers through liquid biopsy
• Molecular approaches to aid early detection of cancer
• Molecular mechanisms of resistance to targeted therapy
• Utility of artificial intelligence for early detection and improving therapy stratification

Professor Don J. L. Jones

• Translation of candidate biomarkers to clinical use.
• Use of high resolution LC-MS in the discovery and verification of biomarkers.
• Investigation of protein quantification using Ion mobility.
• Translation of candidate biomarkers to clinical use.
• Use of high resolution LC-MS in the discovery and verification of biomarkers.
• Investigation of protein quantification using Ion mobility.

Professor Bruno Morgan

• Imaging applications to monitor drug therapy
• Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT

Dr Tim Rattay

• Personalising breast cancer treatment according to predicted toxicity
• Radiogenomics and biomarkers
• Breast surgery and reconstuction
• Patients' views on breast cancer treatment and predictive testing

Professor Jacqui Shaw

• Analysis of circulating cancer biomarkers through liquid biopsy
• Molecular approaches to aid early detection of cancer
• Molecular mechanisms of resistance to targeted therapy

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies
• Improving information exchange in oncology consultations

Dr Harriet Walter

• Delivery of Phase I portfolio across haematological malignancies and solid tumour
• Therapeutic drug development
• Development and assessment of novel agents in the treatment of B-cell malignancies

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies
• Antibody therapy of lymphoid malignancies
• Development and assessment of novel agents for therapy of B-cell malignancies

Dr Esther Moss

• Analysis of circulating endometrial cancer biomarkers through liquid biopsy
• Molecular profiling for improved stratification to immunotherapies
• Robotic surgery for management of endometrial cancer
• Patient-initiated follow up for low-risk endometrial cancer
• Use of ex-vivo models for personalising therapies

Professor Catrin Pritchard

• Mechanisms of RAS/RAF oncogene induced tumour development
• RAF/MAPK signalling in normal and cancer cells
• Ex vivo patient relevant drug testing platforms

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
• Investigating and exploiting metabolic vulnerabilities in carcinogenesis
• Using circulating cell-free DNA for early detection of cancer

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies
• Improving information exchange in oncology consultations

Dr Cristina Tufarelli

• Determine which repetitive elements are active in precancerous and cancerous cells
• Understanding what causes activation of repetitive elements
• Establish activation of which repetitive elements plays functional roles in cancer
• Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy